Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
June 18, 2014 22:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., June 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at...
Revance Therapeutics Announces Proposed Public Offering of Common Stock
June 16, 2014 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a...
Revance Therapeutics Clinical Data to be Presented in "Emerging Technologies" Panel at the International Symposium of Facial Plastic Surgery in New York City
May 21, 2014 20:50 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), announced that the company's proprietary, botulinum toxin (BoNTA) investigational products will be the lead...
Revance Therapeutics, Inc. Announces Participation in Jefferies 2014 Global Healthcare Conference
May 21, 2014 16:20 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Jefferies 2014 Global Healthcare...
Revance Therapeutics Releases First Quarter 2014 Financial Results
May 13, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three months ended March 31, 2014. Revance's operating loss for the...
Revance Appoints Mark A. Prygocki to Its Board of Directors
May 12, 2014 22:25 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
April 29, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and...
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
April 21, 2014 16:55 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the...
Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
March 31, 2014 20:00 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following...
Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
March 26, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.
Recent...